Zurig (Febuxostat 80mg)

Zurig (Febuxostat) 80mg is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout.

ZURIG (Febuxostat) is not recommended for the treatment of asymptomatic hyperuricemia.

Febuxostat DOSAGE

ZURIG (ULORIC) is recommended at 40 mg or 80 mg once daily. The recommended starting dose of ZURIG (ULORIC) is 40 mg once daily. For patients who do not achieve a serum uric acid (sUA) less than 6 mg/dL after 2 weeks with 40 mg, ZURIG (ULORIC) 80 mg is recommended.

• ZURIG (ULORIC) can be administered without regard to food or antacid use.

• Limit the dose of ZURIG (ULORIC) to 40 mg once daily in patients with severe renal impairment.

CONTRAINDICATIONS

ZURIG (ULORIC) is contraindicated in patients being treated with azathioprine or mercaptopurine

WARNINGS AND PRECAUTIONS (SIDE EFFECT)

1.Gout Flare: An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including ZURIG (ULORIC). If a gout flare occurs during treatment, ZURIG (ULORIC) need not be discontinued. Prophylactic therapy (i.e., non-steroidal anti-inflammatory drug [NSAID] or colchicine upon initiation of treatment) may be beneficial for up to six months.

2.Cardiovascular Events: A higher rate of cardiovascular thromboembolic events was observed in patients treated with ZURIG (ULORIC) than allopurinol in clinical trials. Monitor for signs and symptoms of MI and stroke

3.Hepatic Effects: Post marketing reports of hepatic failure, sometimes fatal. Causality cannot be excluded. If liver injury is detected, promptly interrupt ZURIG (ULORIC) and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart ZURIG (ULORIC) if liver injury is confirmed and no alternate etiology can be found.

4.Serious Skin Reactions: Post marketing reports of serious skin and hypersensitivity reactions, including Stevens-Johnson Syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) and toxic epidermal necrolysis (TEN) have been reported in patients taking ZURIG (ULORIC). Discontinue ZURIG (ULORIC) if serious skin reactions are suspected.

Zurig is a generic xanthine oxidase medicine from Zydus, which is one of the biggest pharmaceutical company in India.

Febuxostat PI

For more Prescribing information，please check the → “FDA Prescribing Information”.